Resource Type

Journal Article 2

Year

2019 1

2015 1

Keywords

dasatinib 2

allogeneic hematopoietic stem cell transplantation 1

chronic myeloid leukemia 1

chronic myeloid leukemia (CML) 1

imatinib 1

long-term follow-up 1

nilotinib 1

tyrosine kinase inhibitor 1

open ︾

Search scope:

排序: Display mode:

Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult

Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang

Frontiers of Medicine 2015, Volume 9, Issue 3,   Pages 304-311 doi: 10.1007/s11684-015-0400-4

Abstract: Although second-generation TKIs (TKI2), including dasatinib and nilotinib, are appropriateIn the TKI2 group, 26 and 7 patients received nilotinib and dasatinib, respectively,These results indicated that allo-HSCT may be superior to nilotinib and dasatinib for adult patients

Keywords: chronic myeloid leukemia     imatinib     dasatinib     nilotinib     allogeneic hematopoietic stem cell transplantation    

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 344-353 doi: 10.1007/s11684-018-0639-7

Abstract: Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloidIn 2007, a pivotal phase-2 study of dasatinib as second-line treatment was initiated in 140 Chinese CMLThe initial dosage of dasatinib for CML-CP and CML-AP patients were 100 mg once daily and 70 mg twiceThe adverse event (AE) profile of dasatinib at 4 years was similar to that at 6 and 18 months.These long-term follow-up data continue to support dasatinib as a second-line treatment for Chinese patients

Keywords: chronic myeloid leukemia (CML)     dasatinib     tyrosine kinase inhibitor     long-term follow-up    

Title Author Date Type Operation

Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult

Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang

Journal Article

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Journal Article